BioAge’s BGE-102 Achieves Strong Brain Penetration and 98% IL-1 Suppression in Interim Phase 1 Results

Phase 1 Results Highlight Robust Efficacy and Safety Profile for BGE-102

BioAge Labs (NASDAQ: BIOA) announced interim results from its ongoing Phase 1 trial for BGE-102, a structurally novel, orally available NLRP3 inhibitor designed to target both peripheral and central nervous system inflammation. According to the data released as of December 4, 2025, BGE-102 demonstrated high brain penetration and remarkable suppression of IL-1—a key inflammatory cytokine—raising interest about its potential as a best-in-class treatment for metabolic diseases driven by age-related inflammation.

BGE-102: Key Findings Point to Potential Competitive Advantage

Across both single (SAD) and multiple ascending dose (MAD) cohorts, BGE-102 was well tolerated at doses ranging from 10 to 120 mg, with adverse events that were infrequent, mild to moderate, and resolved without intervention. Pharmacokinetic data support once-daily oral dosing. Importantly, BGE-102 achieved dose-dependent suppression of IL-1, reaching 90% reduction at the 60 mg dose and up to 98% at 120 mg by Day 14. These levels of suppression are among the highest reported in this class of drugs to date.

High Brain Penetration Sets BGE-102 Apart from Competitors

What truly distinguishes BGE-102 is its ability to cross the blood-brain barrier: CSF (cerebrospinal fluid) concentrations at 60 mg and higher doses exceeded the target IC90 after 14 days. This opens the door for the drug to impact central inflammation as well as peripheral disease processes—an important advantage, given NLRP3's involvement in both cardiovascular and neurodegenerative conditions.

Expansion to High-Risk Populations Aims for Proof-of-Concept on Inflammation Biomarkers

Building on these results, BioAge is expanding the trial to include MAD cohorts in obese participants with elevated high-sensitivity C-reactive protein (hsCRP), a widely recognized biomarker of inflammation and cardiovascular risk. The next key milestone will be data from this cohort in the first half of 2026, as the company aims to show meaningful reductions in both IL-1 and hsCRP. These data could lay the groundwork for BGE-102's Phase 2a study, planned for 2026, targeting roughly 100 patients in a 12-week, placebo-controlled trial with hsCRP change as the primary endpoint.

BGE-102 Targets Both Peripheral and Central Inflammation

NLRP3 inhibition has become a major focus for age-related inflammatory diseases due to its upstream position in the inflammation cascade, impacting cardiovascular, neurodegenerative, and metabolic disorders. The high brain penetration and strong IL-1 suppression shown by BGE-102 in healthy and obese volunteers suggest the potential to affect not just blood markers but also neurological disease processes—setting a high bar for competing molecules in the NLRP3 class.

What to Watch: Phase 2 Plans and Data in 2026

Investors and clinicians should watch for two major milestones: the MAD cohort data in obese participants with high inflammation in 1H 2026, and the Phase 2a study results later that year. Should these studies confirm sustained and meaningful reductions in IL-1 and hsCRP with continued safety, BGE-102 could quickly move toward pivotal trials in cardiometabolic and possibly neuroinflammatory conditions.

Key Milestones to Track

Takeaway: Data Supports BGE-102’s Broad Inflammation-Fighting Promise

While it’s still early in clinical development, the interim Phase 1 data for BGE-102 support its promise as a novel inflammation-modulating therapy that can cross into the brain and powerfully suppress a key driver of chronic disease. With more rigorous data expected from larger cohorts in 2026, BGE-102 could become a pivotal molecule in addressing diseases linked to inflammation and metabolic aging. Anyone interested in the evolving landscape of inflammation therapies may want to follow these upcoming milestones closely.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI